Haematological malignancies - Clinical Focus


Our work is focussed primarily in two areas. In allotransplantation, we are focussed on understanding the immunological mechanisms underlying the potent Graft-versus-Leukaemia (GvL) effect, and also Graft-versus-Host Disease (GvHD), a common cause of post-transplant mortality. A key aim is to selectively boost GvL, and we are working on both vaccination and adoptive transfer approaches to achieve this.

A second, complementary focus is on epigenetic modification, a strategy that offers the prospect of using novel chemotherapy drugs to both suppress GvHD responses, and to enhance expression of tumour associated antigens that can be targeted by T cells.

These approaches are the subject of several ongoing clinical trials, and synergise strongly with our basic research on tumour associated antigens and immunotherapeutic strategies.